ClariVest Asset Management’s Pacira BioSciences PCRX Stock Holding History

ClariVest Asset Management’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$2.75K	Hold	96	–	–	﹤0.01%	491
2024 Q2	$2.75K	Buy	96 +61	+174%	+$1.74K	﹤0.01%	491
2024 Q1	$1.02K	Hold	35	–	–	﹤0.01%	656
2023 Q4	$1.18K	Hold	35	–	–	﹤0.01%	631
2023 Q3	$1K	Hold	35	–	–	﹤0.01%	689
2023 Q2	$1K	Hold	35	–	–	﹤0.01%	626
2023 Q1	$1K	Sell	35 -2	-5%	-$80	﹤0.01%	678
2022 Q4	$1K	Hold	37	–	–	﹤0.01%	649
2022 Q3	$2K	Hold	37	–	–	﹤0.01%	545
2022 Q2	$2K	Sell	37 -4,417	-99%	-$289K	﹤0.01%	563
2022 Q1	$340K	Sell	4,454 -6	-0.1%	-$400	0.01%	430
2021 Q4	$269K	Hold	4,460	–	–	0.01%	471
2021 Q3	$249K	Hold	4,460	–	–	0.01%	474
2021 Q2	$271K	Hold	4,460	–	–	0.01%	473
2021 Q1	$312K	Hold	4,460	–	–	0.01%	460
2020 Q4	$267K	Buy	4,460 +4,400	+7,333%	+$258K	0.01%	474
2020 Q3	$4K	Hold	60	–	–	﹤0.01%	572
2020 Q2	$3K	Buy	+60	New	+$2.51K	﹤0.01%	668

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

ClariVest Asset Management's PCRX Position: Q3 2024 in Review

ClariVest Asset Management held its Pacira BioSciences (PCRX) position steady in Q3 2024 at 96 shares worth $2.75K. The position accounts for ﹤0.01% of the portfolio, ranked #491.

ClariVest Asset Management first reported a position in PCRX in Q2 2020 and has held it in 18 quarters since. The position peaked at $340K in Q1 2022. 239 funds tracked by Wall St. Rank hold PCRX as of Q3 2024.

ClariVest Asset Management held 96 shares of Pacira BioSciences worth $2.75K as of Q3 2024.
ClariVest Asset Management left its Pacira BioSciences share count unchanged in Q3 2024.
Pacira BioSciences made up ﹤0.01% of ClariVest Asset Management's portfolio in Q3 2024, its #491 holding.
ClariVest Asset Management first reported a position in Pacira BioSciences in Q2 2020 and has held it in 18 quarters since.
ClariVest Asset Management's Pacira BioSciences position peaked at $340K in Q1 2022.
239 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2024.

Based on ClariVest Asset Management's 13F filing for Q3 2024, filed 12 Nov 2024.